POU SHENG INT'L (03813) announced its mid-2026 results, with shareholder profit attributable to owners at 244 million yuan, an increase of 29.9% year-on-year.
P&R International (03813) announced its performance for the six months ended June 30, 2026, with operating revenue of 8.9646 billion yuan (RMB, the same below), a year-on-year decrease of 2.1%; profit attributable to the company's owners was 244 million yuan, a year-on-year increase of 29.9%; basic earnings per share were 4.70 cents, with a proposed interim dividend of 0.016 Hong Kong dollars per share and a special dividend of 0.016 Hong Kong dollars per share.
POU SHENG INT'L (03813) announced its results for the six months ended June 30, 2026, with operating revenue of RMB 8.9646 billion, a year-on-year decrease of 2.1%; net profit attributable to owners of the company was RMB 244 million, an increase of 29.9% compared to the previous year; basic earnings per share was 4.70 cents, with an interim dividend proposed at HKD 0.016 per share and a special dividend also proposed at HKD 0.016 per share.
During this period, the groups total operating revenue decreased by 2.1%, while the group continuously improved operational efficiency and implemented strategic dynamic inventory management. At the same time, it built a comprehensive one-stop operation, narrowing the year-on-year decline in revenue, with direct retail channels outperforming franchise channels.
Related Articles
ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.
CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.
ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.
CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.
RECOMMEND
